Enhancing medication adherence with blister-packed oral oncolytics: A case example in chronic lymphocytic leukemia
- PMID: 39969400
- DOI: 10.1177/10781552241306704
Enhancing medication adherence with blister-packed oral oncolytics: A case example in chronic lymphocytic leukemia
Abstract
Introduction: Medication nonadherence is a prevalent issue in the oncology population and can be costly on the healthcare system while leading to worsened outcomes, including increased mortality. One intervention that has been shown to help promote medication adherence to oral therapies for chronic conditions is blister-packaging. However, no literature is available assessing the potential impact of blister-packaging in oncology. Therefore, we aimed to quantify the impact of blister-packaging oral oncolytics on medication adherence and healthcare costs.
Methods: An economic model was designed to assess the potential impact of blister-packaging oral oncolytics for chronic lymphocytic leukemia (CLL) patients in the U.S. The model took the perspective of the U.S. healthcare system and assessed newly diagnosed CLL cases initiating therapy, utilizing a one-year time horizon. The intervention of interest was blister-packaging oral therapies in the treatment of CLL, while the model evaluated the impact of this intervention on healthcare costs through improved patient adherence based on peer-reviewed literature.
Results: This analysis consisted of 20,700 newly diagnosed patients with CLL initiating therapy. Initiating blister-packed oral therapies saw adherence increase by 1004 patients from 12,979 patients (62.7%) to 13,983 patients (67.5%). While an increase in pharmacy costs by $61,589,670 (+$247.95 per-patient per-month (PPPM)) was seen for the population, medical costs decreased by $82,285,847 (-$331.26 PPPM). Overall, this led to a net reduction in total healthcare costs of $20,696,177 (-$83.32 PPPM).
Conclusions: Blister-packaging oral oncology drugs in CLL has the potential to reduce total healthcare expenditures by increasing medication adherence. Future studies are needed to evaluate the direct effects of blister-packaging oral oncolytics on clinical, healthcare resource utilization, and financial outcomes.
Keywords: Blister-packing; healthcare costs; hematologic malignancies; medication adherence; medication adherence packaging.
Conflict of interest statement
Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Saad, Dumitru, Nelkin, and Lucaci are employees and shareholders of Becton, Dickinson and Company. Borrelli and Barnes are employees of Becton, Dickinson and Company. Barnes is a shareholder of BioMerieux. No other conflicts of interest to report.
Similar articles
-
Improving Adherence and Reducing Health Care Costs Through Blister-Packaging: An Economic Model for a Commercially Insured Health Plan.Clinicoecon Outcomes Res. 2024 Oct 3;16:733-745. doi: 10.2147/CEOR.S480890. eCollection 2024. Clinicoecon Outcomes Res. 2024. PMID: 39376478 Free PMC article.
-
Enhancing Outcomes in Opioid Use Disorder Treatment: An Economic Evaluation of Improving Medication Adherence for Buprenorphine Through Blister-Packaging.Subst Abuse Rehabil. 2024 Oct 22;15:209-222. doi: 10.2147/SAR.S484831. eCollection 2024. Subst Abuse Rehabil. 2024. PMID: 39463862 Free PMC article.
-
Estimating the economic impact of blister-packaging on medication adherence and health care costs for a Medicare Advantage health plan.J Manag Care Spec Pharm. 2024 Dec;30(12):1442-1454. doi: 10.18553/jmcp.2024.24179. Epub 2024 Sep 11. J Manag Care Spec Pharm. 2024. PMID: 39258999 Free PMC article.
-
Evaluating the efficacy of blister packaging in improving medication adherence within psychiatry: A systematic literature review.Ment Health Clin. 2025 Jun 2;15(3):176-186. doi: 10.9740/mhc.2025.06.176. eCollection 2025 Jun. Ment Health Clin. 2025. PMID: 40496006 Free PMC article. Review.
-
Oral oncolytic treatment for chronic lymphocytic leukemia.J Oncol Pharm Pract. 2022 Jun;28(4):935-944. doi: 10.1177/10781552211073906. Epub 2022 Jan 27. J Oncol Pharm Pract. 2022. PMID: 35084245 Review.
LinkOut - more resources
Full Text Sources